Quantcast

Latest Cytotoxicity Stories

2010-07-08 07:30:00

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases...

2010-06-23 05:00:00

PRINCETON, N.J., June 23 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline (GSK). BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). The second license agreement provides GSK...

2009-12-08 11:54:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Pharmacodynamic Assays http://www.reportlinker.com/p0167260/Pharmacodynamic-Assays.html Pharmacodynamic assays are assays that provide methods for quickly screening cell samples for a pharmacodynamic effect to a drug or test agent. These assays inform drug development decisions by providing evidence of drug action on molecular targets. Pharmacodynamic assay...

2009-11-11 15:00:00

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana. The presentations will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating...

2009-10-21 05:00:00

PRINCETON, N.J. and WALTHAM, Mass., Oct. 21 /PRNewswire/ -- BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. The agreement grants NKTT non-exclusive rights to research, develop, manufacture and commercialize antibodies targeting...

2009-10-05 16:00:00

PRINCETON, N.J., Oct. 5 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). BioWa's first Japanese pharmaceutical POTELLIGENT® License was initiated in May,...

2009-03-19 02:00:00

LONDON, March 19 /PRNewswire/ -- The 2009 Frost & Sullivan European Drug Discovery Product Innovation Award is presented to Xenometrix AG in recognition of its active role in the production of single and multiple endpoint cytotoxicity assays. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) These test kits, used in the early screening stages of drug discovery, improve the effectiveness of drug discovery and development through lead optimisation. One product line - the IN...

2008-12-22 11:06:04

Owing to the novel properties of carbon nanotubes (CBNs), a series of problems associated with in vitro toxicity assessments of carbon nanotubes (CNTs) have appeared in many literatures. In order to properly evaluate the potential risk to human health, the cell toxicity assay of CBNs can not be conducted by traditional methods employed in common toxicology. Ying Zhu and Wenxin Li in Laboratory of Nano-biology and Medicine, Shanghai Institute of Applied Physics, Shanghai, P. R.China gave this...

2008-08-28 09:01:23

The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an important target for several antibody- and small molecule-based inhibitors specific for various RTKs for the treatment of different tumour entities. The electrical impedance detection method with Roche's real-time cell microelectronic sensor-based platform xCELLigence system is a facile, high content, and cell based kinase assay allowing for monitoring short term RTK activation...

2005-11-16 14:32:11

UC Davis Cancer Center researchers have discovered a genetic switch that causes cancer cells to become more sensitive to a drug administered to enhance radiation therapy effectiveness. The switch does not make the drug more toxic. The discovery may help scientists design new anti-cancer agents that enhance the effectiveness of radiation therapy with less toxicity than currently available radiosensitizing drugs. The finding is reported in the Priority Reports section of the last issue of the...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related